CAMBRIDGE, Mass. — Vyome Holdings Inc. has licensed two selective JAK inhibitor assets from Impetis Biosciences Limited, a TATA Enterprise, expanding its pipeline in immunology and inflammatory disease.
The Cambridge-based company said the agreement gives Vyome exclusive rights to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Vyome said the assets could position the company in a global JAK inhibitor market projected to reach about $57 billion by 2030.
JAK inhibitors are immunomodulatory drugs used to treat autoimmune and inflammatory conditions by blocking Janus kinase enzymes. Several drugs in the class have been approved by the U.S. Food and Drug Administration for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, alopecia areata and atopic dermatitis.
Vyome said the licensed assets are designed to be more selective than earlier pan-JAK approaches, potentially improving safety. The company said some older-generation JAK inhibitors have faced safety warnings because they are less selective.
“We are delighted that Impetis trusted the Vyome team to lead the development of such valuable assets. We believe that selective JAK inhibitors are the future in immunology, and that Impetis has provided compelling preclinical data to show the clear differentiation from early generation JAK inhibitors,” said Shiladitya Sengupta, M.D., co-founder of Vyome and associate professor of medicine at Harvard Medical School. “While we remain focused on the development of our lead asset, VT-1953 for symptoms of malignant fungating wound, a major unmet need in cancer patients, these JAK inhibitors expand our portfolio and allow us to expand to new and large immune-inflammatory therapeutic areas in the future.”
Vyome said the transaction strengthens its ability to source differentiated innovation across the U.S.-India corridor while preserving its focus on VT-1953. The company described the structure as capital-efficient, with consideration tied to commercialization and future development expected through non-dilutive pathways.
“We are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion by 2034, with the JAK inhibitor segment alone representing a significant ~$57 billion opportunity,” said Venkat Nelabhotla, CEO of Vyome. “This transaction highlights the strength of the US–India innovation corridor in sourcing high-quality assets efficiently. The transaction is structured to be very capital-efficient, with consideration tied to commercialization. Any future development will be driven through non-dilutive pathways, allowing us to remain fully focused on executing our core strategy around VT-1953.”
Impetis said the partnership reflects its effort to move preclinical programs toward clinical value.
“We are pleased to partner with Vyome on the development of our JAK inhibitor programs,” said KRS Jamwal, chairman of Impetis. “This partnership reflects Impetis’ ongoing commitment to translating its deep preclinical portfolio into clinical value.”
